CLINICAL TRIALS

Our Studies

At SVG Pharma, we are dedicated to advancing rigorous, evidence-based clinical research across emerging therapeutic technologies, including medicinal cannabis, microbiome interventions, and mental health treatments. Every study we conduct adheres to Good Clinical Practice (GCP), ICH guidelines, and Australian regulatory standards, ensuring the highest levels of scientific integrity, patient safety, and ethical oversight.

Our lean, insight-driven approach, supported by advanced technologies and operational expertise, ensures efficient, cost-effective delivery of clinical trials. This allows us to support both Australian and international sponsors, enabling smooth cross-border regulatory pathways while maintaining the quality and compliance needed for robust evidence generation.

Where We're Focused

We are committed to advancing emerging therapeutic solutions through high-quality clinical research. Our current and upcoming studies are designed to generate robust evidence supporting safe, effective treatments, with one recent trial completed and others in development.

Genesis Study

Design: Phase III, double-blind, randomised, placebo-controlled trial

Partner: In collaboration with Australian Natural Therapeutics Group (ANTG)

Focus: Evaluation of cannabinoid (CBD) oil formulation for the management of abdominal pain in patients with Irritable Bowel Syndrome (IBS)
Study Status: Completed as of January 2025.

Results: Preliminary findings are supporting an upcoming Schedule 3 (S3) submission to the TGA, demonstrating translational impact from clinical evidence to regulatory progression

Metadora Study

Design: Phase II, double-blind, randomised, open-label study

Partner: NektarTek Pty Ltd

Focus: Investigating the efficacy of cannabinoid-based therapies for the treatment of dysmenorrhea

Study Status: Currently undergoing ethics and regulatory approvals; recruitment anticipated early 2026.

Eligibility: Female participants residing in Tasmania and Victoria

Nausea & Vomiting Study

Design: Phase III, double-blind, randomised, placebo-controlled trial

Partner: In discussions.

Focus: Accessing the potential of cannabinoid-based treatments to manage induced nausea and vomiting.

Study Status: In development phase, designed to generate high-quality, globally relevant clinical evidence

Supporting safe access through science

Our clinical trials contribute to a growing body of evidence for emerging therapeutic interventions, helping sponsors translate innovative science into clinically validated therapies. We combine patient-centered design, regulatory expertise, and lean operational models to ensure every study meets the highest standards of quality, compliance, and efficiency.